The VA just doubled the runway
The Department of Veterans Affairs has received approval to extend the performance period of its Federal Supply Schedule (FSS) contracts. Historically, VA FSS contracts ran for a five-year base period plus a single five-year option — a 10-year maximum performance period. The new structure doubles that runway to 20 years, and the VA has announced an upcoming mass modification to implement the change across active contracts.
If you hold a VA FSS — particularly if you sell pharmaceuticals, medical/surgical supplies, or healthcare-related services through the FSS program — this is the most consequential VA contracting change of 2026.
I want to walk through what changed, why it matters, and the strategic moves contractors should be making now.
What changed
The VA shared in April 2026 that it has approval to change and extend the performance period of FSS contracts. The legacy structure was:
- Five-year base period.
- Plus one five-year option.
- Total: 10 years.
The new structure extends the total performance period to 20 years. Implementation will come through a mass modification — meaning every existing VA FSS holder will be offered the extended period via a bilateral modification, similar in mechanics to how GSA mass modifications work under the MAS program.
For pharmaceutical manufacturers, this aligns more cleanly with product lifecycles. A drug brand can be in market for 15–20 years; running a federal contract that resets every 5 to 10 years has long created administrative friction without policy benefit.
Why this matters more than it looks
A longer contract performance period sounds like a simple administrative win. It is not. Three reasons it matters strategically:
1. Pricing strategy resets less often
Every contract end-of-period is a pricing reset point. For VA FSS contracts that sit under the Federal Ceiling Price (FCP) framework for covered drugs (38 U.S.C. 8126), the government already has substantial pricing leverage. But the 5- and 10-year contract reset cycles created additional negotiation leverage — agencies could threaten non-renewal to extract concessions. A 20-year performance period changes that dynamic.
2. Modifications become the primary contract action
If your contract runs 20 years, the modification cycle is your primary contract administration discipline. Adding products, removing discontinued NDCs, updating clinical labeling, refreshing pricing — all of this happens through modifications under your contract PIID. If your modification process is sloppy today, a 20-year contract is going to expose every weakness.
3. Compliance exposure compounds
A 20-year contract is a 20-year compliance window. Every certification you make at award — under FAR 52.219-1 (Small Business Program Representations) at the time, under your Trade Agreements Act compliance representations, under VA FSS-specific certifications about non-FAMP pricing — has to remain current and defensible. The OIG has a long memory and a long audit horizon. Twenty years of clean compliance is harder than 10.
What to do with the mass modification
When the mass mod arrives, do not sign it on autopilot. A few specific things to check:
Read every clause being inserted or updated
Mass modifications are unilateral in form — GSA and VA both phrase them as "accept by date X or face contract action" — but they are bilateral in legal effect. You sign, you are bound. Read what you are signing. Particularly look for:
- Updated TAA-compliant country lists and country-of-origin representations.
- Updated cybersecurity and supply-chain risk management clauses.
- Any new pricing or sales reporting language (the VA is not currently TDR but watch for any data-sharing additions).
- Updated socioeconomic representations under FAR 52.212-3 or the equivalent commercial-item representation flow-down.
Verify your covered drug list
For pharma holders, the FCP-covered drug list and your non-covered drug list need to be exactly current. A 20-year contract is not the time to discover that a discontinued NDC is still on your contract or that a new product line has not been added.
Confirm your contracting officer of record
When I worked acquisitions, contracting officer rotations were the single most common reason a contract drifted out of compliance. A 20-year contract is going to outlast multiple contracting officers. Document who your CO is today, who your contract specialist is today, and what their open action items are. Build a contract file that the next CO can pick up cleanly.
Stress-test your pricing for the new horizon
If you accept a 20-year performance period, you are committing to a pricing structure across that horizon — subject to your contract's economic price adjustment provisions. For pharma contractors, the FCP framework provides some statutory protection. For medical/surgical and healthcare services contractors, the EPA clause is your insurance policy. Read it carefully and confirm you can live with it across a 20-year horizon.
Strategic implications
A few practical effects to think through:
- Acquisition due diligence on VA FSS portfolios will get harder. A 20-year contract is a more valuable asset, but also a longer compliance tail. M&A buyers will price the extended performance period in — and the diligence questions will be sharper.
- Pricing transparency requests will continue to escalate. A longer contract gives the VA more time to ask pricing-justification questions. Build internal documentation as if you will be asked to defend every price every year.
- Competitor displacement gets harder. If your competitor signs a 20-year FSS, you cannot count on natural contract churn to open the door. Your displacement strategy has to lean on product differentiation or pricing pressure inside the modification cycle, not on waiting for contract expiration.
When I was a CO, long contracts always favored disciplined contractors
Every long-period contract I administered favored the contractor with disciplined contract administration. Modifications were processed cleanly. Sales reporting was accurate. Past performance was strong. Those contractors got their option exercises, their modifications, and their pricing requests approved. The contractors with sloppy contract administration got friction at every step.
The VA's 20-year extension is a structural advantage for disciplined contractors and a structural risk for everyone else.
Bottom line
The VA FSS performance period extension to 20 years is a meaningful change. When the mass modification arrives, read it carefully, verify your covered drug and product lists, and confirm your contracting officer of record. Build a contract file that survives multiple CO rotations and 20 years of audit exposure. The contractors who treat this extension as an administrative win without upgrading their contract administration discipline will pay for it in the second decade. The contractors who use it to lock in operational excellence will hold a strategic advantage that compounds.